Canagliflozin Lowers Postprandial Glucose and Insulin by Delaying Intestinal Glucose Absorption in Addition to Increasing Urinary Glucose Excretion: Results of a randomized, placebo-controlled study

OBJECTIVE: Canagliflozin, a sodium glucose cotransporter (SGLT) 2 inhibitor, is also a low-potency SGLT1 inhibitor. This study tested the hypothesis that intestinal canagliflozin levels postdose are sufficiently high to transiently inhibit intestinal SGLT1, thereby delaying intestinal glucose absorp...

Descripción completa

Detalles Bibliográficos
Autores principales: Polidori, David, Sha, Sue, Mudaliar, Sunder, Ciaraldi, Theodore P., Ghosh, Atalanta, Vaccaro, Nicole, Farrell, Kristin, Rothenberg, Paul, Henry, Robert R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2013
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3714520/
https://www.ncbi.nlm.nih.gov/pubmed/23412078
http://dx.doi.org/10.2337/dc12-2391

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3714520/
https://www.ncbi.nlm.nih.gov/pubmed/23412078
http://dx.doi.org/10.2337/dc12-2391

Ejemplares similares